Connect with us


Glaucoma Drug Gets FDA Approval; Company to Hire 100 Sales Reps




It’s the firm’s ‘single greatest achievement.’

Aerie Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved Rhopressa 0.02% for the lowering of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.  

The approval decision was made two months ahead of the scheduled Prescription Drug User Fee Act goal date of Feb. 28.

“The approval of once-daily Rhopressa represents the single greatest achievement in Aerie’s history to date, and represents exciting news for patients with open-angle glaucoma or ocular hypertension, and physicians,” said Vicente Anido Jr., chairman and CEO at Aerie. “It is a testament to years of successful research and development and the incredible talents of our dedicated employees, to whom we owe much gratitude.” 

Anido said the company will hire 100 sales representatives early in the first quarter of 2018.


The company said Rhopressa (netarsudil ophthalmic solution) 0.02% “is believed to reduce IOP by increasing the outflow of aqueous humor (the fluid inside the eye) through the trabecular meshwork, the main fluid drain of the eye.”


Sponsored by Varilux

Introducing the VariluxⓇ Challenge

You’re faced with a variety of progressive lenses to recommend to your patients, but they are not created equal. When Eyecare Professionals insisted on Varilux lenses with every presbyopic patient for 30 days, not only did they provide sharp, seamless vision so that their patients could truly see no limits, but they also created trust, loyalty and increased profitability. See for yourself and take the Varilux Challenge today at

#VariluxChallenge #InsistOnVarilux

Promoted Headlines





Get the most important news and business ideas for eyecare professionals every weekday from INVISION.


Most Popular